What is Cagrilintide?
The Long-Acting Amylin Analogue Explained.
A comprehensive research guide to cagrilintide — the long-acting amylin analogue increasingly studied alongside GLP-1 agonists for synergistic metabolic effects.
Cagrilintide is a long-acting, acylated analogue of the human hormone amylin, engineered for once-weekly dosing with a half-life of approximately 7 days. While GLP-1 agonists like Tirzepatide and Retatrutide have dominated metabolic research, cagrilintide represents a distinct and complementary approach — targeting the amylin and calcitonin receptor pathways to modulate satiety through mechanisms that are largely independent of the incretin axis.
What is Amylin?
Amylin (Islet Amyloid Polypeptide / IAPP) is a 37 amino acid peptide co-secreted with insulin by pancreatic beta cells in response to food intake. It works alongside insulin to regulate postprandial glucose levels but through different mechanisms — primarily by slowing gastric emptying, suppressing glucagon, and generating satiety signals in the brainstem and hypothalamus.
Native amylin has a very short half-life (minutes) and poor solubility, making it impractical as a research reagent. Cagrilintide was developed as a stable, long-acting analogue with dramatically improved pharmacokinetic properties.
Mechanism of Action.
Cagrilintide acts as a non-selective agonist at amylin receptors — which are heterodimers of the calcitonin receptor combined with receptor activity-modifying proteins (RAMPs). This gives cagrilintide activity at multiple receptor complexes simultaneously:
Calcitonin Receptor (CTR)
The core component of all amylin receptor subtypes — the structural backbone of the heterodimer.
CTR + RAMP1
Primary satiety signalling pathway, expressed in the area postrema of the brainstem.
CTR + RAMP2
Implicated in broader metabolic regulation across peripheral tissues.
CTR + RAMP3
Drives central nervous system satiety pathways, particularly within the hypothalamus.
Cagrilintide + GLP-1 Agonist Research.
One of the most significant developments in metabolic peptide research has been the combination of cagrilintide with semaglutide — a protocol known in research circles as “CagriSema.” The rationale is compelling: GLP-1 and amylin pathways modulate satiety through different neural circuits and receptor systems, suggesting genuine additive or synergistic effects when both are activated simultaneously.
| Property | Cagrilintide | Semaglutide | Combined |
|---|---|---|---|
| Primary Receptor | Amylin / Calcitonin | GLP-1R | Both pathways |
| Satiety Mechanism | Brainstem / Area Postrema | Hypothalamus | Dual CNS sites |
| Gastric Emptying | Strong suppression | Moderate | Enhanced |
| Glucagon Suppression | Yes | Yes | Synergistic |
| Half-Life | ~7 days | ~7 days | Compatible dosing |
Compound Profile.
| Property | Detail |
|---|---|
| Structure | Acylated analogue of human amylin with a fatty-acid side chain for albumin binding and substitutions that reduce fibrillation |
| Formula & weight | C194H312N54O59S2 · about 4,409 g/mol · CAS 1415456-99-3 |
| Half-life | About 7–8 days, supporting once-weekly administration |
| Developer | Novo Nordisk |
| Status (September 2026) | Investigational. CagriSema (with semaglutide) is under FDA review; cagrilintide alone is in the phase 3 RENEW programme |
Key Published Research.
| Study | What it found |
|---|---|
| Development (2021) | Novo Nordisk described designing cagrilintide as a long-acting, non-fibrillating amylin analogue suitable for weekly dosing.1 |
| Phase 2 monotherapy (2021) | Over 26 weeks, cagrilintide produced dose-dependent weight loss, reaching 10.8% at the highest dose versus 3.0% on placebo and 9.0% with liraglutide 3.0 mg.2 |
| Phase 1b with semaglutide (2021) | Combining cagrilintide with semaglutide 2.4 mg was well tolerated and produced greater weight loss than semaglutide alone.3 |
| Phase 2 in type 2 diabetes (2023) | CagriSema produced greater weight loss than either component alone in people with type 2 diabetes.4 |
| REDEFINE 1 (2025) | In adults with obesity, CagriSema produced 20.4% mean weight loss at 68 weeks versus 3.0% with placebo.5 A later Novo Nordisk analysis reported 11.8% weight loss with cagrilintide alone. |
| REDEFINE 2 (2025) | In adults with obesity and type 2 diabetes, CagriSema produced 13.7% mean weight loss versus 3.4% with placebo.6 |
Research & Regulatory Status (2026).
| Date | Development |
|---|---|
| December 2025 | Novo Nordisk submitted a New Drug Application to the FDA for once-weekly CagriSema; a decision is expected in the fourth quarter of 2026. |
| Q4 2025 | A dedicated phase 3 programme for cagrilintide monotherapy (RENEW) was scheduled to begin. |
| 2026 | In REDEFINE 4, an 84-week open-label head-to-head trial in 809 adults, CagriSema produced 23.0% weight loss versus 25.5% with tirzepatide and did not meet its non-inferiority endpoint. |
Evidence Quality & Limitations.
Cagrilintide’s clinical programme is large and well controlled, but almost all of it has been run by its developer. Gastrointestinal effects are the most common adverse events, as with GLP-1 agonists. Comparisons across separate trials — for example CagriSema versus tirzepatide — are unreliable, which is why REDEFINE 4’s direct comparison matters. Entries such as “Synergistic” in the combination table above describe the mechanistic rationale rather than measured interaction effects.
References.
- Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64:11183–94. PubMed
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160–72. PubMed
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736–48. PubMed
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402:720–30. PubMed
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393:635–47. PubMed
- Davies MJ, et al. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025;393:648–59. PubMed
